A prospective, non-randomized, open label clinical study of a Restorative Pulmonary Heart Valve in Right Ventricular Outflow Tract (RVOT) reconstruction.
The Xplore-2 trial is actively enrolling patients. Please contact the enrolling trial centers for any enquiries.
XPLORE-2 IS A CLINICAL RESEARCH STUDY ON AN INVESTIGATIONAL DEVICE NOT APPROVED FOR USE IN THE USA.
PLEASE NOTE: XELTIS CANNOT PROVIDE ANY INFORMATION TO INDIVIDUAL PATIENTS AND THEIR CLINICIANS IN RELATIONS TO CLINICAL TRIALS, DUE TO PRIVACY AND CLINICAL PRACTICE REGULATIONS.
The Xplore-2 trial is actively enrolling patients.
Please contact the enrolling trial centers for any enquiries.
A RESTORATIVE PULMONARY VALVE
The options currently available for Right Ventricular Outflow Tract (RVOT) reconstruction, from homografts to mechanical and animal-derived pulmonary valves present some limitations:
- They may have limited durability, in particular for young patients due to calcification and stenosis leading to repeated interventions
- Or require life-long anticoagulation therapy, with potentially severe side effects
- Or require a long wait, since donated homografts are in short supply
To address these limitations, the medical device company Xeltis developed a new generation of restorative heart valves to enable the body to restore new, living heart valves with patient’s own tissue. They have a highly porous micro-structure, designed to allow the patient’s tissue to infiltrate it and gradually restore a fully functional, living valve.
This process is called Endogenous Tissue Restoration (ETR). Such implants have a potential to reduce post-operative device-related complications and to adapt to the overall body growth They may therefore enable a completely new treatment approach in heart valve therapy.
ENDOGENOUS TISSUE RESTORATION (ETR)
ETR IN ACTION
RESULTS TO DATE
To date 18 patients have been successfully implanted with Xeltis restorative pulmonary valves in the USA, Europe and Asia as part of the Xplore-1 and Xplore-2 trials.
Patients have been carefully followed up and evidence from more than 60 patient/years confirmed the positive safety profile of this novel technology.
Results from existing trials on Xeltis restorative technology have been published in peer-reviewed publications:
- Morales D et al. Restorative pulmonary valve, one and two-year results in patients. Frontiers in Cardiovascular Medicine
- Bennink G et al. Restorative pulmonary valve in preclinical studies. The Journal of Thoracic and Cardiovascular Surgery
- Jewell C. Synthetic valves in one-year animal studies. Science Translational Medicine
- Webber M et al. Supramolecular biomaterials. Nature Materials